论文部分内容阅读
目的:随着表皮生长因子受体酪氨酸酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitor,EGFR-TKI)在非小细胞肺癌(Non-Small Cell Lung Cancer,NSCLC)治疗中的应用,患者的生活质量及生存期均有很大程度的提高,但是,组织表皮生长因子受体(epidermal growth factor receptor,EGFR)检测结果为能否接受EGFR-TKI治疗的先决条件,而晚期肺癌患者却因组织量少、质量不佳、组织异质性无法进行检测,血液EGFR检测便应运而生,本研究将综述晚期非小细胞肺癌(Non-Small Cell Lung Cancer,NSCLC)患者血液EGFR基因检测研究。方法:检索Pub-med、SCI、Medline及中国生物文献数据库中晚期非小细胞肺癌患者血液EGFR基因检测的相关研究。结果:对于晚期NSCLC患者,血液EGFR基因检测有较高的敏感度与特异度,并且能够较好的预测患者对EGFR-TKI的疗效以及进行耐药监测。结论:当组织获取困难及质量不佳时,血液可替代组织行EGFR基因检测。
Objective: With the application of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in the treatment of non-small cell lung cancer (NSCLC), patients However, the test results of tissue epidermal growth factor receptor (EGFR) are the prerequisites for the treatment of EGFR-TKI, whereas patients with advanced lung cancer Small amount of tissue, poor quality, tissue heterogeneity can not be detected, blood EGFR detection came into being, this study will review the blood of advanced non-small cell lung cancer (Non-Small Cell Lung Cancer, NSCLC) EGFR gene detection. Methods: A retrospective study was conducted on the detection of EGFR gene in blood of patients with advanced non-small cell lung cancer by Pub-med, SCI, Medline and Chinese biological literature database. Results: In patients with advanced NSCLC, the blood EGFR gene test has higher sensitivity and specificity, and can better predict the efficacy of EGFR-TKI and monitor the drug resistance. Conclusion: When the tissue is difficult to obtain and the quality is poor, the blood can replace the tissue line EGFR gene detection.